Patients shouldn’t have to battle their insurer for the medicine their doctor prescribed. Insurer and PBM mega-consolidation lets middlemen raise costs and restrict access. Washington must act.

The reality is spending on medicines is padding the profits of middlemen, often at the expense of patients. It’s time to pass savings on to patients and hold middlemen like PBMs and insurers accountable.

Even when they get billions of dollars in rebates and discounts that can reduce the cost of brand medicines by 50% or more, PBMs make patients pay full price. We can lower costs by holding PBMs and insurers accountable. https://t.co/QywpjpeZeH

PBMs and insurers can steer patients to the pharmacies they own at the expense of patients and the government, drawing extensive investigation by the FTC and Congress. Stop PBMs and insurers from driving up costs:

PhRMA is happy to welcome our new member, @Stemline, a biopharmaceutical company focused on improving outcomes for people living with cancer. They join a growing list of member companies advocating for U.S. biopharmaceutical leadership and delivering better outcomes for patients.

Changes to the U.S. childhood vaccine schedule weaken protections for kids—without new scientific justification. Rotavirus, flu & RSV still threaten infants and young children. We should keep evidence‑based recommendations strong. Read the blog:

There are plenty of myths floating around about ADHD medications, but 80% of children with ADHD see symptoms improve with the right stimulant medication and dose. Get the facts about ADHD meds.

In yet another major milestone in American drug discovery, @EliLillyandCo has announced their new AI co-innovation lab in collaboration with @nvidia, with a joint investment of $1 billion. Read more about the partnership working to discover the cures of tomorrow:

A new radioligand therapy (RLT) manufacturing facility from @NovartisUS in Florida, highlights our industry's commitment to investing in American communities and bringing reliable treatment to patients. Learn more: https://t.co/F2Vn5Qe4tx

Tax-exempt hospitals blame drug prices for 340B growth. The data tells a different story. 340B expansion is driven by abusive hospital behavior, not pricing. Growth without guardrails isn’t a success story, it’s time for 340B reform.

As PBMs push more costs onto patients, manufacturers are stepping up with direct purchase programs—keeping prices transparent for patients. But these programs aren’t a fix-all. PBM reform is still needed to address the root causes of high costs and access barriers.

With more than 80% of their R&D investment based in the U.S., @GileadSciences is advancing treatments for cancer and inflammatory diseases & supporting American jobs and scientific leadership. Hear more from CEO Daniel O’Day on how their $32B investment supports U.S. innovation.

🚀 $500B committed to U.S. innovation & manufacturing 💰 $1.6T in economic output 🏭 1,500+ facilities in 48 states 👩‍🔬 5M high-skilled jobs 🎓 111M students in STEM Biopharma’s commitment to Americans is strong. Continued growth depends on a stable policy environment.

A recent Bloomberg investigation revealed how some tax-exempt hospitals charge cancer patients huge markups for lifesaving medicines. Read more here:

Decisions about mental health treatment should be part of a doctor-patient relationship. It’s time to set the record straight and break the stigma so that patients and their families can feel comfortable seeking treatment.

Our innovation series highlighted bold investments in American R&D and manufacturing — new facilities, growing workforces, and expanded production that strengthen America’s global leadership. A year marked by growth, momentum, and putting American patients first.

As 2025 wraps, one thing is clear: America is investing in its future. Biopharmaceutical companies have committed $500B to U.S. research, manufacturing and jobs — strengthening America’s leadership in medical innovation and supporting patients and communities nationwide.

340B hospitals can buy medicines at steep discounts, markup the price by thousands of dollars and pocket the difference. It’s time for Congress to put big hospitals on the Naughty List and reform 340B.

PBMs have made their wishlist clear — more control, more restrictions, and higher costs for patients. It’s up to policymakers to stop it.